Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005664809
Wed, 03.01.2024
Evotec SE
DR WERNER LANTHALER TO STEP DOWN AS CEO
REMAINS AVAILABLE AS STRATEGIC ADVISOR TO THE SUPERVISORY BOARD TO FACILITATE A SMOOTH TRANSITION
DR MARIO POLYWKA HAS AGREED TO STEP IN AS INTERIM CEO
SEARCH STARTED FOR PERMANENT CEO TO CONTINUE BUILDING THE GLOBALLY LEADING COMPANY FOR EXTERNAL INNOVATION
EVOTEC CONFIRMS GUIDANCE 2023
Hamburg, Germany [ … ]
Wed, 03.01.2024
Evotec SE
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to serve until the end of his current term, for personal reasons. The Supervisory Bo [ … ]
Tue, 19.12.2023
Evotec SE
EVOTEC JOINS THE BILL & MELINDA GATES FOUNDATION FUNDED GLOBAL HEALTH DISCOVERY COLLABORATORY (“GHDC”) AS A NEW ADDITION TO THE FIFTEEN COLLABORATORY PLATFORMS
GRANT FROM THE BILL & MELINDA GATES FOUNDATION PROVIDES GHDC MEMBER INSTITUTIONS WITH ACCESS TO EVOTEC’S IPSC-DERIVED HIGH-THROUGHPUT TERATOGENICITY PLATFORM
Hamburg, Germany, 19 [ … ]
Thu, 14.12.2023
Evotec SE
GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF ANCA-ASSOCIATED VASCULITIS
CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN WILL COLLECT BIOSAMPLES FROM ANCA-ASSOCIATED VASCULITIS PATIENTS
EVOTEC WILL LEVERAGE ITS UNIQUE PANOMICS TECHNOLOGIES TO IMPROVE PATIENT STRATIFICATION AND CREATE NEW ENTRY POINTS FOR PRECISION MEDICINE [ … ]
Wed, 06.12.2023
Evotec SE
EVT201 APPROVED BY THE CHINESE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (“NMPA”) AS A NOVEL SHORT-TERM TREATMENT OF INSOMNIA
EVOTEC’S LICENCE PARTNER ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD (“JINGXIN”) WILL LEAD ALL COMMERCIALISATION EFFORTS FOR EVT201 IN CHINA AND SOUTH KOREA
Hamburg, Germany, 06 December 2023:
Evotec SE (Frankfurt Stock Exc [ … ]
Wed, 15.11.2023
Evotec SE
PRECISION MEDICINE CAPABILITIES SHAPING (NEW) MARKETS WITH FIRST-IN-CLASS THERAPEUTICS
PANOMICS, IPSC & A.I./M.L. PLATFORMS ARE THE STEP CHANGE FOR GROWTH AND ACCELERATED PIPELINE BUILDING
CONFIRMATION OF ACTION PLAN 2025 GOALS AND PROGRESS UPDATE
Hamburg, Germany, 15 November 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN [ … ]
Wed, 08.11.2023
Evotec SE
CONTINUATION OF STRONG GROWTH IN DEMANDING MARKETS
PARADIGM-SHIFTING OFFERINGS ARE STRONGEST GROWTH DRIVERS
PIPELINE PROGRESS, E.G. WITH ADVANCED ASSET IN NEURODEGENERATION
ALL ELEMENTS OF GUIDANCE CONFIRMED
Hamburg, Germany, 08 November 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announc [ … ]
Tue, 07.11.2023
Evotec SE
STRATEGIC PARTNERSHIP TO ACCELERATE DEWPOINT’S LEADING ONCOLOGY PIPELINE PROGRAMMES TO INVESTIGATIONAL NEW DRUG APPLICATIONS
COLLABORATION LEVERAGES EVOTEC’S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY PLATFORM
AGREEMENT IS BASED ON A RISK-SHARING ARRANGEMENT FOLLOWED BY MILESTONE AND ROYALTY PAYMENTS TO EVOTEC BASED ON SUCCESS OF OVER [ … ]
Wed, 01.11.2023
Evotec SE
Hamburg, Germany, 01 November 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first nine months 2023 on Wednesday, 08 November 2023.
The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conf [ … ]
Thu, 05.10.2023
Evotec SE
A UNIQUE COMPANY CREATION VEHICLE INITIATED BY LIGHTSTONE VENTURES AND EVOTEC SE, AND ESTABLISHED WITH PARTNERS CLAVYSTBIO, LEAPS BY BAYER, POLARIS PARTNERS, AND THE POLARIS INNOVATION FUND
FIRST-OF-ITS-KIND PARTNERSHIP IN SINGAPORE AND ASIA LEVERAGES BREAKTHROUGH SCIENCE FROM RESEARCHERS AT AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (“A*STAR” [ … ]